Attractive stocks have exceptional fundamentals. In the case of Corcept Therapeutics Incorporated (NASDAQ:CORT), there's is a company with great financial health as well as a a strong track record of performance. Below, I've touched on some key aspects you should know on a high level. For those interested in understanding where the figures come from and want to see the analysis, take a look at the report on Corcept Therapeutics here.
Flawless balance sheet with proven track record
Over the past few years, CORT has demonstrated a proven ability to generate robust returns of 26%. Unsurprisingly, CORT surpassed the Pharmaceuticals industry return of 21%, which gives us more confidence of the company's capacity to drive earnings going forward. CORT's ability to maintain an adequate level of cash to meet upcoming liabilities is a good sign for its financial health. This implies that CORT manages its cash and cost levels well, which is an important determinant of the company’s health. CORT currently has no debt on its balance sheet. This implies that the company is running its operations purely on off equity funding. which is typically normal for a small-cap company. Therefore the company has plenty of headroom to grow, and the ability to raise debt should it need to in the future.
For Corcept Therapeutics, there are three important aspects you should look at:
- Future Outlook: What are well-informed industry analysts predicting for CORT’s future growth? Take a look at our free research report of analyst consensus for CORT’s outlook.
- Valuation: What is CORT worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether CORT is currently mispriced by the market.
- Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of CORT? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at firstname.lastname@example.org. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.